News coverage about CTI BioPharma (NASDAQ:CTIC) has trended somewhat positive recently, according to Accern. Accern identifies negative and positive press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. CTI BioPharma earned a daily sentiment score of 0.06 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 47.4823268640794 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

A number of research firms have issued reports on CTIC. Jefferies Financial Group restated a “buy” rating and set a $4.00 price target on shares of CTI BioPharma in a research note on Friday, July 20th. ValuEngine upgraded CTI BioPharma from a “sell” rating to a “hold” rating in a research note on Friday, August 3rd. Zacks Investment Research downgraded CTI BioPharma from a “hold” rating to a “sell” rating in a research note on Thursday, July 12th. JMP Securities set a $8.00 price objective on CTI BioPharma and gave the company a “buy” rating in a research note on Tuesday, July 10th. Finally, BidaskClub downgraded CTI BioPharma from a “strong-buy” rating to a “buy” rating in a research note on Saturday, July 14th. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $5.83.

NASDAQ CTIC traded down $0.13 during trading hours on Friday, reaching $1.95. The company’s stock had a trading volume of 958,020 shares, compared to its average volume of 1,065,382. The company has a current ratio of 4.28, a quick ratio of 5.30 and a debt-to-equity ratio of 0.18. CTI BioPharma has a 1 year low of $1.94 and a 1 year high of $5.36. The stock has a market cap of $120.62 million, a PE ratio of -1.57 and a beta of -0.32.

CTI BioPharma (NASDAQ:CTIC) last posted its quarterly earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($0.20) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.23) by $0.03. CTI BioPharma had a negative return on equity of 90.92% and a negative net margin of 313.77%. The company had revenue of $0.61 million for the quarter, compared to analysts’ expectations of $0.30 million. analysts forecast that CTI BioPharma will post -0.6 EPS for the current fiscal year.

CTI BioPharma Company Profile

CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. It develops PIXUVRI, a novel aza-anthracenedione for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma; and pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase III clinical trials for the treatment of adult patients with myelofibrosis.

See Also: Market Capitalization, Large-Caps, Mid-Caps, Small-Caps

Insider Buying and Selling by Quarter for CTI BioPharma (NASDAQ:CTIC)

Receive News & Ratings for CTI BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CTI BioPharma and related companies with's FREE daily email newsletter.